Sanara MedTech (NASDAQ:SMTI) Upgraded by Wall Street Zen to Buy Rating

Sanara MedTech (NASDAQ:SMTI) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

Several other equities research analysts have also recently weighed in on SMTI. Zacks Research cut Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sanara MedTech in a research note on Thursday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of Sanara MedTech in a report on Monday, January 26th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $36.00.

Sanara MedTech Stock Performance

Shares of NASDAQ:SMTI opened at $16.96 on Friday. The firm has a fifty day simple moving average of $19.99 and a two-hundred day simple moving average of $24.44. Sanara MedTech has a 52 week low of $16.05 and a 52 week high of $35.95. The company has a quick ratio of 1.60, a current ratio of 1.80 and a debt-to-equity ratio of 7.75. The stock has a market capitalization of $155.52 million, a P/E ratio of -4.01 and a beta of 1.04.

Sanara MedTech (NASDAQ:SMTI) last announced its earnings results on Tuesday, March 24th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.07). Sanara MedTech had a negative net margin of 36.42% and a negative return on equity of 20.73%. The business had revenue of $27.55 million for the quarter, compared to analysts’ expectations of $27.90 million. On average, analysts expect that Sanara MedTech will post -1.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sanara MedTech

Hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its position in Sanara MedTech by 351.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock worth $48,000 after purchasing an additional 1,171 shares during the period. Wells Fargo & Company MN boosted its position in shares of Sanara MedTech by 78.1% during the fourth quarter. Wells Fargo & Company MN now owns 3,322 shares of the company’s stock valued at $78,000 after buying an additional 1,457 shares during the period. Lazard Asset Management LLC boosted its position in shares of Sanara MedTech by 63,100.0% during the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock valued at $89,000 after buying an additional 3,155 shares during the period. Deutsche Bank AG grew its stake in shares of Sanara MedTech by 171.1% during the fourth quarter. Deutsche Bank AG now owns 3,985 shares of the company’s stock valued at $93,000 after buying an additional 2,515 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Sanara MedTech by 44.1% in the third quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock worth $101,000 after buying an additional 973 shares during the period. 8.10% of the stock is currently owned by institutional investors.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.